(m-Chlorobenzyl)guanidine | 55172-24-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (m-Chlorobenzyl)guanidine
• 英文别名: 2-[(3-chlorophenyl)methyl]guanidine
• CAS: 55172-24-2
• 化学式: C₈H₁₀ClN₃
• 分子量: 183.64
• InChiKey: CUZPMXGXQZNUDE-UHFFFAOYSA-N

物化性质

• 沸点：
  301.7±44.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  (1H-imidazol-1-yl)(3,5,6-trimethylpyrazin-2-yl)methanone 、 (m-Chlorobenzyl)guanidine 反应 5.0h， 以26.3%的产率得到N-(N-(3-chlorobenzyl)carbamimidoyl)-3,5,6-trimethylpyrazine-2-carboxamide
  参考文献：
  名称：

  Ligustrazine Derivatives. Part 6: Design, Synthesis and Evaluation of Novel Ligustrazinyl Acylguanidine Derivatives as Potential Cardiovascular Agents

  摘要：

  A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.

  DOI：

  10.2174/157340612802084243
• 作为产物：
  描述：

  1-(3-氯苄基)胍亚硫酸盐 在 sodium hydride 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 (m-Chlorobenzyl)guanidine
  参考文献：
  名称：

  Ligustrazine Derivatives. Part 6: Design, Synthesis and Evaluation of Novel Ligustrazinyl Acylguanidine Derivatives as Potential Cardiovascular Agents

  摘要：

  A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.

  DOI：

  10.2174/157340612802084243

文献信息

• [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：RIDEOUT DARRYL

  公开号：WO2016105448A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物，如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物，有些实施例中还提供了对其的调节剂（例如，激动剂）。
• SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS
  申请人：Tandon Manish

  公开号：US20100249108A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的二吡咯-嘧啶-二氮杂环化合物，取代的苯并-二吡咯-嘧啶-二氮杂环化合物以及合成这些化合物的方法。本发明还涉及含有取代的二吡咯-嘧啶-二氮杂环化合物，取代的苯并-二吡咯-嘧啶-二氮杂环化合物的药物组合物，并通过将这些化合物和药物组合物给予需要的受体中，治疗细胞增殖性疾病，如癌症的方法。
• Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity
  作者：Xinrong Xiang、Zhengyi Dai、Baozhu Luo、Ninglin Zhao、Song Liu、Jing Sui、Jiasheng Huang、Yuanzheng Zhou、Jinlong Gu、Jiangnan Zhang、Tao Yang、Rui Bao、Youfu Luo

  DOI：10.1021/acs.jmedchem.4c00338

  日期：2024.4.25

  agonist imipridone ONC201. Here, a novel class of HsClpP agonists is designed and synthesized using a ring-opening strategy based on the lead compound 1 reported in our previous study. Among these novel scaffold agonists, compound 7k exhibited remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 ± 0.03 μM) and antitumor activity in vitro (IC50 = 0.038 ± 0.003 μM). Moreover, the intraperitoneal

  通过化学或遗传策略激活智人酪蛋白裂解蛋白酶 P (HsClpP) 已被证明是治疗急性髓系白血病 (AML) 的一种新的潜在疗法。然而，经典激动剂咪啶酮ONC201的疗效有限。在此，基于我们之前研究中报道的先导化合物1 ，使用开环策略设计并合成了一类新型 HsClpP 激动剂。在这些新型支架激动剂中，化合物7k表现出显着增强的HsClpP蛋白水解活性（EC 50 = 0.79 ± 0.03 μM）和体外抗肿瘤活性（IC 50 = 0.038 ± 0.003 μM）。此外，腹腔注射化合物7k可显着抑制Mv4-11异种移植模型中的肿瘤生长，肿瘤生长抑制率达到88%。同时， 7k在体内表现出有利的药代动力学特性。这项研究强调了化合物7k作为重要的 HsClpP 激动剂和抗白血病候选药物的前景，值得进一步探索 AML 治疗。
• Sympathetic Nervous System Blocking Agents. III. Derivatives of Benzylguanidine^1-3
  作者：James H. Short、Thomas D. Darby

  DOI：10.1021/jm00317a017

  日期：1967.9
• US8349827B2
  申请人：——

  公开号：US8349827B2

  公开（公告）日：2013-01-08